Fierce Pharma Asia—AstraZeneca-CSPC heart med deal; Astellas’ gene therapy pact, new cell therapy site

Fierce Pharma October 11, 2024
Angus Liu

AstraZeneca has bagged a cardiovascular disease candidate from China’s CSPC Pharma in a deal potentially worth $2 billion. Astellas is shuffling its cell therapy research team and investing in a dementia gene therapy candidate. And more.

1. AstraZeneca pays CSPC $100M for preclinical heart disease drug, teeing up combos and Lilly rivalry

AstraZeneca paid China’s CSPC Pharma Group $100 million and committed up to $1.92 billion in milestones for a preclinical oral disruptor of Lp(a), a form of low-density lipoprotein. AZ sees opportunities to develop the drug, YS2302018, as a single agent and in combination with assets including its PCSK9 inhibitor in cardiovascular disease.

2. Astellas unveils new Japan site for cell therapy research arm Universal Cells, transferring 12 roles...

Today's Sponsors

Today's Sponsor